help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GREMBIALE, R. D.
Right arrow Articles by MARSICO, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GREMBIALE, R. D.
Right arrow Articles by MARSICO, S. A.

Am. J. Respir. Crit. Care Med., Volume 162, Number 6, December 2000, 2048-2052

Effects of Specific Immunotherapy in Allergic Rhinitic Individuals with Bronchial Hyperresponsiveness

ROSA D. GREMBIALE, LUIGI CAMPOROTA, SAVERIO NATY, CARMELINDO M. E. TRANFA, RATKO DJUKANOVIC, and SERAFINO A. MARSICO

Department of Experimental and Clinical Medicine, University of Catanzaro, Cantanzaro, Italy; and Division of University Medicine, Southampton General Hospital, Southampton, United Kingdom

Allergic rhinitis can be associated with bronchial hyperresponsiveness (BHR), and carries an increased risk for the development of asthma. The aim of this study was to evaluate the ability of specific immunotherapy (SIT) to reduce the progression of allergic rhinitis to asthma and prevent the associated increase in BHR. Forty-four subjects monosensitized to Dermatophagoides pteronyssinus, with perennial rhinitis and BHR to methacholine, were randomly assigned to receive SIT or placebo in a double-blind study conducted over a period of 2 yr. After 1 yr of treatment, a 2.88-fold increase in the provocative dose of methacholine producing a 20% decrease in FEV1 (PD20FEV1) was recorded in the SIT-treated group (95% confidence interval [CI]: 3.98- to 2.09-fold; p < 0.001), with a further increase to fourfold at the end of Year 2 (95% CI: 2.9- to 5.7-fold; p < 0.001). At the end of the study, the methacholine PD20FEV1 was within the normal range in 50% of treated subjects (p < 0.0001), and was significantly higher in this group than in the group receiving placebo (p < 0.0001). In contrast, no changes in methacholine PD20FEV1 were found in the placebo group throughout the study. Although 9% of subjects given placebo developed asthma, none of those treated with SIT did. This study suggests that SIT, when administered to carefully selected, monosensitized patients with perennial allergic rhinitis, reduces airway responsiveness in subjects with rhinitis, and may be an appropriate prophylactic treatment for rhinitic patients with hyperreactive airways.




This article has been cited by other articles:


Home page
 ChestHome page
S. M. Tarlo, J. Balmes, R. Balkissoon, J. Beach, W. Beckett, D. Bernstein, P. D. Blanc, S. M. Brooks, C. T. Cowl, F. Daroowalla, et al.
Diagnosis and Management of Work-Related Asthma: American College of Chest Physicians Consensus Statement
Chest, September 1, 2008; 134(3_suppl): 1S - 41S.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
Prevention strategies for asthma -- secondary prevention
Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S25 - S27.
[Full Text] [PDF]

Home page
 ChestHome page
A. E. Varner
The Increase in Allergic Respiratory Diseases : Survival of the Fittest?
Chest, April 1, 2002; 121(4): 1308 - 1316.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  ATS Par News